Noticias y vídeos - ORYZON GENOMICS

Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for...

MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune checkpoint inhibitors in first line small cell lung cancer...

Investing in Oncology Forum 2024 Van Lanschot Kempen Life Sciences Conference Swiss Biotech Day 2024 LSX World Congress MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in April. Oryzon has...

Topline data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) reported with promising results in secondary endpoints of overall severity and control of agitation/aggression Company planning to request an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial in BPD Continues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophrenia Continues to recruit patients in FRIDA trial with iadademstat in...

Keystone Symposia Epigenetic Mechanisms and Cancer Treatment Bio-Neuroscience 17 th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international...

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced that it will host a virtual KOL event on Thursday, January 25, 2024 at 10:00 am ET to briefly review, then discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disorder (BPD). To...

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th Sachs Annual Neuroscience Innovation Forum, on January 7 at 3:30 pm PT, at the Marine’s Memorial Club in San Francisco (USA). Results across all efficacy endpoints consistently favored vafidemstat over placebo. Global Statistical Test (GST p-values) confirms consistent trend across efficacy endpoints The primary endpoints, improvement in...

7th Sachs Annual Neuroscience Innovation Forum 13rd Annual LifeSci Advisors Corporate Access Event Biotech Showcase-2024 42nd Annual J.P. Morgan Healthcare Conference Invest Securities Biomed Forum 2024 MADRID, Spain and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an...

Spanish biotech Oryzon Genomics is among the leading clinical-stage drug developers, with a second generation of epigenetic ......

To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration with the ALS Association. The Association has awarded Oryzon a 498,690 USD grant through...

Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous one To extend its cash runway and continue the ongoing clinical trials in CNS and oncology Initial execution of €8 million in two tranches of €4 million each, plus optional additional tranches of up to €5 million each to be executed in the future, at Oryzon’s request, subject to customary conditions MADRID, Spain and BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...

Company on track to report top line data milestone in 1Q 2024 A total of 210 participants have been recruited Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced Last Patient Last...

BIO-Europe 2023 LSX Investival Showcase 2023 Jefferies London Healthcare Conference 2023 MADRID, Spain and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in November. Oryzon will participate in the BIO-Europe...

Positive aggregate safety data from vafidemstat's fully enrolled PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-tolerated Continues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophrenia Continues to recruit patients in FRIDA trial with iadademstat in combination with gilteritinib in relapsed/refractory FLT3-mutant AML patients Research and...

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023) MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company presented an update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the 36th European College of...

Two collaborative projects with public research centers with a global budget of 2.3 million euros Oryzon to receive up to 1.4 million euros Focused on the discovery and validation of novel biomarkers and epigenetic targets for the treatment of neuronal pathologies MADRID, Spain and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet...

East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023) Investor Access 2023 Event Jefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2 nd Healthcare Opportunities Conference ESMO (European Society for Medical Oncology) 2023 congress MADRID, Spain and BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in...

H.C. Wainwright Global Investment Conference in NYC Sachs Annual Biotech in Europe Forum in Basel Third Annual Global CMT Research Convention in Boston BioSpain-2023 in Barcelona MADRID, Spain and BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate...

Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in agitation and aggression and overall disease improvement Topline efficacy data expected in Q1 2024 Recent predefined Interim Analysis qualified PORTICO as non-futile MADRID, Spain and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a...

Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-tolerated Continues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophrenia Continues to recruit patients in FRIDA trial with iadademstat in combination with gilteritinib in relapsed/refractory FLT3-mutant AML patients Cash, cash equivalents and...